Brief: Unicycive Updates NDA for Oxylanthanum Carbonate to Treat CKD-Related Hyperphosphatemia
10/06/2025 11:32
June 10 (Reuters) - Unicycive Therapeutics Inc UNCY.O: UNICYCIVE PROVIDES UPDATE ON NEW DRUG APPLICATION FOR OXYLANTHANUM CARBONATE TO TREAT HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS UNICYCIVE THERAPEUTICS INC - FDA FINAL DECISION ON OLC NDA EXPECTED BY JUNE 28, 2025 UNICYCIVE THERAPEUTICS INC - FDA IDENTIFIES DEFICIENCIES AT THIRD-PARTY MANUFACTURING VENDOR UNICYCIVE THERAPEUTICS INC - FDA IDENTIFIES CGMP COMPLIANCE DEFICIENCIES AT THIRD-PARTY VENDOR Source text: ID:nGNXSJW8K Further company coverage: UNCY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss